BioVie Inc. (NASDAQ: BIVI) completed enrollment of 60 patients in its Phase 2 SUNRISE-PD clinical trial evaluating bezisterim for early-stage ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE